Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ: REGN )

922.79 -4.54 (-0.49%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 30, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 628,782
Open 919.73
Bid (Size) 915.00 (1)
Ask (Size) 994.00 (1)
Prev. Close 927.33
Today's Range 914.85 - 935.86
52wk Range 772.84 - 1,211.20
Shares Outstanding 91,779,465
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights
Novartis aims to enhance Pluvicto's market presence while exploring growth in multiple sclerosis and expanding its radioligand therapy portfolio. 
Via Benzinga
EyePoint's Investigational Drug Shows Early And Sustained Improvement Than Regeneron's Eylea For Diabetes-Associated Vision Loss
EyePoint Pharmaceuticals' shares rise as interim Phase 2 VERONA trial data shows Duravyu improves visual acuity and anatomy in diabetic macular edema patients. 
Via Benzinga

Performance

YTD
+1.97%
+1.97%
1 Month
-12.22%
-12.22%
3 Month
-14.49%
-14.49%
6 Month
+2.14%
+2.14%
1 Year
+18.32%
+18.32%

More News

Read More
Stock-Split Watch: 2 Healthcare Stocks That Look Ready to Split
Via The Motley Fool
Eli Lilly's Newly FDA-Approved Eczema Drug Improves Skin And Itch In Patients Previously Treated With Sanofi/Regeneron's Dupixent
Via Benzinga
$100 Invested In This Stock 15 Years Ago Would Be Worth $5,800 Today
Via Benzinga
A Closer Look at 23 Analyst Recommendations For Regeneron Pharmaceuticals
Via Benzinga
Exploring The Competitive Space: Regeneron Pharmaceuticals Versus Industry Peers In Biotechnology
Via Benzinga
Dupixent® (dupilumab) Late-Breaking Positive Phase 3 Data in Chronic Spontaneous Urticaria to Be Presented at ACAAI
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Seagate To Rally More Than 24%? Here Are 10 Top Analyst Forecasts For Wednesday
Via Benzinga
Market Whales and Their Recent Bets on REGN Options
Via Benzinga
Healthcare Sector Update: Choppy Days Are Here Again As Yields Rise
Via Talk Markets
What the Options Market Tells Us About Regeneron Pharmaceuticals
Via Benzinga
Inquiry Into Regeneron Pharmaceuticals's Competitor Dynamics In Biotechnology Industry
Via Benzinga
A Closer Look at 24 Analyst Recommendations For Regeneron Pharmaceuticals
Via Benzinga
Market Whales and Their Recent Bets on REGN Options
Via Benzinga
Three-year Results for EYLEA HD® (aflibercept) Injection 8 mg Demonstrate Continued Durable Vision Gains and Anatomic Improvements with Extended Dosing Intervals in Patients with Diabetic Macular Edema
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Healthcare Sector Update: Life in the Slow Lane while we wait for BIOTECH Bounce
Via Talk Markets
Here's How Much $100 Invested In Regeneron Pharmaceuticals 15 Years Ago Would Be Worth Today
Via Benzinga
These 3 Stocks Are Screaming Oversold: Seize the Opportunity
Via MarketBeat
Topics ETFs Earnings
Exposures Financial
(REGN) - Analyzing Regeneron Pharmaceuticals's Short Interest
Via Benzinga
$100 Invested In This Stock 5 Years Ago Would Be Worth $400 Today
Via Benzinga
Biden Administration Unveils Plan To Provide Generic Drugs for $2 to Medicare Recipients
Via Benzinga
Regeneron Chief Flags Health Risks with Popular Weight-Loss Medications Like Ozempic, Says Company Targets Muscle Preservation For Its Obesity Drugs
Via Benzinga
Should You Buy the Dip on This Top Growth Stock?
Via The Motley Fool
Regeneron Pharma, Super Micro Computer And Global Payments Are Among Top 10 Large Cap Losers Last Week (Sept 23-Sept 27): Are The Others In Your Portfolio?
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.